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Abstract
Introduction: The uptake of HIV testing and linkage to care remains low among men, contributing to high HIV incidence in
women in South Africa. We conducted the “Home-Based Intervention to Test and Start” (HITS) in a 2x2 factorial cluster ran-
domized controlled trial in one of the World’s largest ongoing HIV cohorts in rural South Africa aimed at enhancing both
intrinsic and extrinsic motivations for HIV testing.
Methods: Between February and December 2018, in the uMkhanyakude district of KwaZulu-Natal, we randomly assigned 45
communities (clusters) (n = 13,838 residents) to one of the four arms: (i) financial incentives for home-based HIV testing and
linkage to care (R50 [$3] food voucher each); (ii) male-targeted HIV-specific decision support application, called EPIC-HIV; (iii)
both financial incentives and male-targeted HIV-specific decision support application and (iv) standard of care (SoC). EPIC-HIV
was developed to encourage and serve as an intrinsic motivator for HIV testing and linkage to care, and individually offered to
men via a tablet device. Financial incentives were offered to both men and women. Here we report the effect of the interven-
tions on uptake of home-based HIV testing among men. Intention-to-treat (ITT) analysis was performed using modified Poisson
regression with adjustment for clustering of standard errors at the cluster levels.
Results: Among all 13,838 men ≥ 15 years living in the 45 communities, the overall population coverage during a single round
of home-based HIV testing was 20.7%. The uptake of HIV testing was 27.5% (683/2481) in the financial incentives arm,
17.1% (433/2534) in the EPIC-HIV arm, 26.8% (568/2120) in the arm receiving both interventions and 17.8% in the SoC arm.
The probability of HIV testing increased substantially by 55% in the financial incentives arm (risk ratio (RR)=1.55, 95% CI:
1.31 to 1.82, p < 0.001) and 51% in the arm receiving both interventions (RR = 1.51, 95% CI: 1.21 to 1.87 p < 0.001), com-
pared to men in the SoC arm. The probability of HIV testing did not significantly differ in the EPIC-HIV arm (RR = 0.96, 95%
CI: 0.76 to 1.20, p = 0.70).
Conclusions: The provision of a small financial incentive acted as a powerful extrinsic motivator substantially increasing the
uptake of home-based HIV testing among men in rural South Africa. In contrast, the counselling and testing application which
was designed to encourage and serve as an intrinsic motivator to test for HIV did not increase the uptake of home-based testing.
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1 | INTRODUCTION
Despite the successes and implementation of population-wide
HIV prevention and treatment programmes [1,2], female
adolescents and young women have consistently faced a high
risk of HIV infection, whereas HIV incidence steadily
decreased among males, widening the gender gap in many
generalized HIV epidemic settings [3–6]. Men are less likely to
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test for HIV and link to care once tested positive, leading to
worse long-term health outcomes such as unsuppressed viral
load and higher HIV-related mortality among males and recip-
rocally high HIV incidence among females [1,7]. In rural South
Africa, once antiretroviral therapy (ART) coverage among
males surpassed 35% in 2014, population-level HIV incidence
among females significantly declined [8].
Recent community-based trials of universal testing and treat-
ment (UTT) including our Test-as-Prevention (TasP) trial (ANRS
12249) in rural South Africa achieved no significant or some-
what modest reduction in HIV incidence at the population level
[9–12]. One of the key challenges consistent across these trials
was missing men and young people – who were disproportion-
ally reached and consented for HIV testing, and less likely to
link to and remain in care [12]. The trials highlighted that it is
not sufficient to merely provide home-based HIV counselling
and testing and universal treatment, but effective strategies
must be accompanied to increase the uptake of HIV counselling
and testing (HCT) and linkage to care at clinics.
Financial incentives have been used to promote various
healthy behaviours such as medication adherence [13], reduc-
tion of substance misuse [14], or use of preventive services
including voluntary medical male circumcision [15–17].
Recently, several clinical trials showed promising results that
financial incentives could increase the uptake of HIV testing
as well as linkage to care and viral load suppression but the
efficacy has been varying [18–26]. While financial incentives
may serve as once-off extrinsic motivation, providing informa-
tion specific to individuals’ needs can improve intrinsic motiva-
tion and empower individuals to make an informed decision to
take HCT [27,28].
To our knowledge, no study has explicitly quantified the
effect of extrinsic vs. intrinsic motivators on the uptake of
HIV testing. We conducted a factorial cluster randomized clini-
cal trial – Home-based Intervention to Test and Start (HITS) –
in rural KwaZulu-Natal. This trial was built upon the Africa
Health Research Institute (AHRI)’s ongoing population-based
HIV testing platform. Since 2017, AHRI started offering
home-based rapid HIV testing to all eligible individuals during
annual HIV surveys. The uptake of home-based rapid HIV test-
ing in 2017 was 26.4% in the overall population and 20.0%
among men [29]. The overall aim of the trial is to establish
whether the provision of small once-off financial incentives
and a male-targeted HIV-specific decision support application
increases uptake of HIV testing and linkage to HIV care, thus
ultimately reducing population-level HIV incidence in (particu-
larly young) women. Here we report the uptake of home-
based HIV testing among men, the first registered primary
endpoint of the HITS trial.
2 | METHODS
2.1 | Setting
The trial was nested within the population-based HIV testing
platform in uMkhanyakude district of northern KwaZulu Natal
[30]. HIV prevalence in the study area was estimated as 36.6%
in 2016 [31]. Since 2003, AHRI has conducted ongoing popula-
tion-based demographic surveillance and individual HIV testing
among members of all households residing in the surveillance
area. The demographic surveillance is completed with the key
informant, which is often the household head or the most
senior household member and collects information on demo-
graphics of household members including composition, migra-
tion events, mortality and marital status. The HIV surveillance is
annually conducted among all residents aged ≥ 15 years and
collects data on sexual behavior and general health and dried
blood spots (DBS) samples for anonymized HIV testing after
obtaining informed consent [30,32]. No reimbursement is
offered for participation in the HIV surveillance. From 2017,
rapid HIV testing has been offered as part of the HIV surveil-
lance during household visits. The surveillance covers 438 km2
geographic area over approximately 90,000 individuals and 60
000 residents at any given time. Through an agreement with
the South African Department of Health, the AHRI population-
based programme is also linked with the clinical records of
patients enrolled in the local public HIV Treatment and Care
Programme at the Hlabisa district hospital and 17 primary
health care clinics in the Hlabisa health sub-district using the
Tier.Net electronic record system since 2004 [33]. For the
patients who out-migrate or link to care outside the 17 clinics,
their clinical records could not be captured.
2.2 | Trial design
This large-scale trial was a 2x2 factorial design delivered to a
population of 37,028 residents aged ≥ 15 years in the four
strata with the two interventions, financial micro-incentives
and a male-targeted HIV-specific decision support, called
EPIC-HIV (Empowering People through Informed Choices for
HIV), in 45 clusters (“week blocks”) using the AHRI’s ongoing
population-based annual HIV testing platform (Figure 1) [34].
A week block is an area where fieldworkers visit homesteads
and complete annual surveys in each week; this was devel-
oped using a GPS-based methodology to provide an equiva-
lent workload to cover the entire surveillance area annually
[35]. Over the entire study duration, eight communities
received only the financial micro-incentives (i.e. financial incen-
tives only arm), eight communities received only EPIC-HIV (i.e.
EPIC-HIV only arm), eight communities received both inter-
ventions (i.e. financial incentives plus EPIC-HIV arm or com-
bined arm) and 21 communities received standard of care
(SoC). Both males and females were eligible to receive the
financial incentives but only males were eligible to receive
EPIC-HIV. Implementation and acceptance of the HITS inter-
vention were evaluated using process evaluation through
post-intervention satisfaction surveys as well as focus group
and in-depth interviews among study participants, fieldworkers
and health professionals. The trial was registered at the
National Institute of Health (ClinicalTrials.gov #
NCT03757104), and the full trial protocol was published else-
where [34].
2.3 | Home-based HIV counselling & testing and
facilitated linkage to care
As part of the individual HIV surveillance, a rapid point-of-care
HIV test is performed by field workers trained in HCT in
accordance with the South African national guidelines. Partici-
pants found to be HIV-positive are encouraged to link to care
within seven to ten days of the HIV test date, receive a refer-
ral slip for an appointment to receive HIV care at their choice
Tanser FC et al. Journal of the International AIDS Society 2021, 24:e25665
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25665/full | https://doi.org/10.1002/jia2.25665
2
of the primary health clinics, and can opt in for facilitated link-
age. Individuals who consent for facilitated linkage and have
not linked to care within two weeks of the HIV test date
receive a single Short Message Service (SMS) message as a
reminder. If individuals do not link to care within further two
weeks, a trained nurse contacts them by telephone to discuss
any concerns and encourage them to link to care. Individuals
who were not available at the initial attempt of contact to
complete the HIV surveillance are revisited two more times in
the same week during normal working hours and then trans-
ferred to a tracking team who then attempts to contact par-
ticipants and make a home visit for three more times in the
evenings or weekends before being considered as missing.
2.4 | Interventions
The interventions were delivered in a two-stage scheme for
HIV testing and linkage to care. For the financial incentives,
participants were first informed and offered a R50 (US ~$3)
food voucher for a local supermarket conditional on their par-
ticipation in rapid HIV testing. Second, participants who tested
HIV-positive were offered another R50 food voucher if they
visited any of the 17 primary health clinics to seek HIV treat-
ment within six weeks of the positive HIV test date.
The male-targeted HIV-specific decision support applica-
tion was implemented and offered via a tablet and available
in two versions (EPIC-HIV 1 and EPIC-HIV 2). The content
and design of EPIC-HIV were informed by human behaviour
change theory and self-determination theory [36]. The appli-
cation development is described in detail elsewhere [34].
EPIC-HIV 1 was delivered to men prior to the HIV test
offer to support their decision whether to take a rapid HIV
test or not. The app was designed to be administered in 5
to 10 minutes. Participants were able to privately self-
navigate the application using a provided earphone and lis-
ten to the story of a chosen character. If participants did
not link to HIV care within a month of a positive HIV test,
a study tracker re-visited and offered them another coun-
selling application (EPIC-HIV 2), which is designed to
address barriers to seek HIV treatment and encourage them
to link to HIV care.
2.5 | Participants
Individuals were eligible if they were aged ≥ 15 years and
residents of the households within the study area in the 45
clusters, agree to participate in the annual HIV surveillance,
and willing to give written informed consent for trial participa-
tion. At randomization, we estimated that of approximately
37,000 eligible participants in the 45 clusters, a total of 4667
individuals would receive HITS interventions in the 24 inter-
vention clusters and 4900 individuals the standard-of-care in
the 21 clusters, considering the expected contact rates and
participation rates in the annual population-based HIV testing
[34]. Written informed consent was sought for trial participa-
tion from all eligible individuals ≥ 18 years, whereas parental/-
guardian consent with child assent was sought for eligible
individuals aged 15 to 17 years.
Individuals were excluded from participation in the study if
they have refused to participate in the annual population-
based HIV testing or report to be already on ART. Individuals
who self-reported as HIV-positive but not on ART were eligi-
ble to participate.
2.6 | Outcomes
We report the uptake of home-based HIV testing among men,
the first registered primary endpoint of the HITS trial. Uptake
Figure 1. Flow diagram for HITS trial. Flow diagram shows individual flow through each stage of the cluster randomized controlled trial by
intervention arms. EPIC, Empowering People through Informed Choices for HIV.
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was defined as acceptance and completion of home-based HIV
testing (with the standard pre- and post-test HIV counselling).
2.7 | Randomization and blinding
Randomization was conducted to ensure balance across the
arms using stratified sampling at the community-level based
on the HIV incidence among young females aged 15 to
30 years. The 45-week blocks (i.e. community clusters) were
divided into four strata according to their HIV incidence rates
such that stratum 1 comprised community clusters with the
lowest incidence rate, whereas stratum 4 comprised commu-
nity clusters with the highest incidence rate. Each of the inter-
vention arms consisted of two community clusters from each
of the four incidence strata (thus a total of eight community
clusters per arm). The SoC arm consisted of five community
clusters from each of the incidence stratum 1, 2 and 4, and
six community clusters from incidence stratum 3 (thus a total
of 21 community clusters). The trial was an open-labelled
without blinding neither to investigators nor participants.
2.8 | Sample size and power calculation
The study was powered to achieve a 25% reduction in HIV
incidence among females aged 15 to 30 years in the interven-
tion arms. Using the AHRI’s actual HIV incidence data, we
estimated to be able to detect a 25% reduction in HIV inci-
dence in the financial incentives only arm, 25% reduction in
the EPIC-HIV only arm and a 37% reduction in the combined
arm after three years of follow-up in > 80% of the power of
simulation replicates (p < 0.05), accounting for grouping of
the clusters in the four arms. Therefore, if we were to intro-
duce the HITS intervention in 2018 and follow young females
for at least three years post-intervention (i.e. utilize a total of
17 years of incidence from 2004 to 2021), we would expect
to be in excess of 90% power to detect such a reduction in
incidence among females aged 15 to 30 years.
2.9 | Implementation
The trial statistician (AD) performed the stratified randomiza-
tion of communities prior to intervention rollout. Fieldwork
teams enrolled and offered interventions to participants when
eligible. Individual consent was sought after cluster randomiza-
tion.
2.10 | Statistical methods
The primary analysis was conducted using the intent-to-treat
(ITT) analysis for all men randomized at the community level.
We used generalized linear models with Poisson distribution
and robust error terms, adjusting for community-level cluster-
ing through random effects. We also examined the effect of
financial incentives and EPIC-HIV separately in the factorial
analysis and interaction effects between the two interventions.
We then limited the analysis to those who participated in the
population-based annual HIV survey and were offered the
interventions. All analyses were conducted in STATA 15.1
(StataCorp) and R 3.5.2. The supporting CONSORT checklist
and flowchart are available as supplemental information
(Figure S1 CONSORT Checklist; Text S1 CONSORT Flowchart).
2.11 | Ethics statement
The study protocols for the AHRI’s population-based HIV test-
ing platform and HITS intervention were approved by the
Biomedical Research Ethics Committee of the University of
KwaZulu-Natal (BE290/16 and BFC398/16) [34]. Permission
for the trial was obtained from the KwaZulu-Natal Depart-
ment of Health, South Africa. Participation in the HIV surveil-
lance and HITS trial is completely voluntary. Individuals may
choose to opt out or refuse to answer any component of the
HIV surveillance and to withdraw at any time. Written
informed consent was sought from individuals
aged ≥ 18 years, and parental or guardian consent with child
assent for individuals of 15 to 17 years old were obtained.
3 | RESULTS
Overall, all 15,488 men living in the 45 clusters in the study
area were initially considered eligible for inclusion in the first
primary outcome of the trial – uptake of testing among men.
Study participants were enrolled from February 2018 to
December 2018. Of these, 1650 died or out-migrated. Of the
13,838 remaining eligible men, 4444 (32.1%) were never con-
tacted (mainly due to absence at the time of HIV testing
despite several attempts to follow-up), 4522 (32.7%) chose
not to participate in the annual population-based HIV testing
in 2018, and 453 (3.3%) reported being on ART, thus result-
ing in 4419 (31.9% of the resident population) who partici-
pated in the population-based HIV testing (Figure 1).
Randomization successfully achieved balance in respect of HIV
prevalence and sociodemographic variables across the four
arms except for the area of residency (Table 1). Those who
participated in the population-based HIV testing were signifi-
cantly younger, compared to those who were never contacted
or chose not to participate (Table S1).
Among all 13,838 men ≥ 15 years living in the 45 communi-
ties in 2018, overall testing coverage was 27.4% (680/2481) in
the financial incentives only arm, 17.0% (430/2534) in the
EPIC-HIV only arm, 26.7% (566/2120) in the financial incen-
tives plus EPIC-HIV arm and 17.7% (1189/6703) in the SoC
arm. In ITT analysis, compared to men in the SoC arm, the
probability of HIV testing was 55% higher in the financial
incentives only arm (risk ratio (RR)=1.55, 95% CI: 1.31 to 1.82,
p < 0.001) and 51% higher in the financial incentives plus
EPIC-HIV arm receiving both interventions (RR = 1.51, 95% CI:
1.21 to 1.87, p < 0.001). The probability of HIV testing was not
significantly different in the EPIC-HIV only arm (RR = 0.96,
95% CI: 0.76 to 1.20, p = 0.70) (Table 2; Figure 2).
When we examined HIV testing uptake by each of the
interventions, the provision of financial incentives increased
the uptake of home-based HIV testing by 55% (RR = 1.55,
95% CI: 1.34 to 1.79). EPIC-HIV did not have any effect on
the uptake of HIV testing at the time of testing offer
(RR = 1.05, 95% CI: 0.85 to 1.30, p = 0.64). There was no
interaction between financial incentives and EPIC-HIV (p-
value = 0.91).
When we limited the analysis to those who participated in
the ongoing population-based HIV testing and thus were
offered the interventions, 76.2% (680/893) in the financial
incentives only arm, 75.8% (566/747) in the combined arm,
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62.1% (430/692) in the EPIC-HIV only arm and 57.0% (1189/
2087) in the SoC arm consented and received the rapid HIV
testing (Figure 1). Compared to men in the SoC arm, the
probability of HIV testing was 34% higher in the financial
incentives only arm (RR = 1.34, 95% CI: 1.24 to 1.45,
p < 0.001) and 33% higher in the combined arm receiving
both interventions (RR = 1.33, 95% CI: 1.20 to 1.48,
p < 0.001). The probability of HIV testing was not significantly
different in the EPIC-HIV only arm (RR = 1.09, 95% CI: 0.98
to 1.21, p = 0.10).
4 | DISCUSSION
In this study, we found that a small non-cash financial incen-
tive (US$ 3) designed to provide an extrinsic motivation to
test substantially increased the uptake of home-based HIV
testing by more than 50% when offered either alone or in
combination with a male-targeted HIV-specific decision sup-
port application. In contrast, the decision support application
designed to act as an intrinsic motivator did not improve the
uptake of home-based HIV testing at the time of testing offer.
Our study is the first large trial to test the effects of extrinsic
versus intrinsic motivators on uptake of home-based HIV test-
ing specifically tailored and targeted to men.
A few studies have shown the positive effect of financial
incentives on the uptake of HCT. In recent randomized con-
trolled trials conducted in sub-Saharan Africa, financial incen-
tives (i.e. both non-cash and cash incentives) significantly
increased the uptake of HIV testing among men in Malawi
[19] or adolescents in Zimbabwe [20]. On the other hand,
most of the previous cash transfer programmes among
women and girls, which focused on changing sexual behaviours
through creating positive social protection, found non-signifi-
cant or marginal effects [37]. Our results provide strong evi-
dence that the relatively small once-off micro-incentives can
play an important role in overcoming a barrier for accepting
HIV testing at a home environment among men.
There are several explanations as to why financial incentives
were well accepted and significantly increased the uptake of
HIV testing among men in this trial. We provided a fixed
financial incentive which offered immediate, tangible and easy-
to-use benefit to everyone in the assigned intervention arms,
rather than in some delayed manner or a chance of receiving
it (i.e. lottery). In Malawi, while fixed incentives improved the
uptake of HIV self-testing kits among men by up to 34%, the





EPIC-HIV EPIC-HIV only Standard of care
HIV prevalence in 2018, % (95% CI)a 18.5 (15.9 to 21.3) 15.0 (12.4 to 17.9) 19.3 (16.2 to 22.7) 17.6 (15.9 to 19.5)
Time since last HIV test in the surveillance (years),
median (IQR)
2.5 (0.6, 6.0) 2.3 (1.0, 5.3) 2.3 (1.0, 5.6) 2.3 (1.0, 5.5)
Individual-level factors n = 2481 n = 2120 n = 2534 n = 6703
Age (years), % (n)
15 to 25 36.5 (906) 37.6 (796) 35.6 (902) 37.2 (2492)
25 to 35 22.5 (558) 23.4 (495) 22.3 (566) 23.4 (1566)
35 to 45 16.5 (410) 13.9 (295) 15.8 (400) 15.7 (1051)
45 to 55 10.4 (258) 10.2 (217) 10.1 (257) 9.7 (647)
≥55 14.1 (349) 14.9 (315) 16.1 (409) 14.1 (946)
Marital status, % (n)
Never married 26.9 (668) 25.9 (550) 26.2 (664) 26.8 (1798)
Married 14.2 (352) 14.6 (309) 15.6 (396) 14.2 (951)
Informal Union 40.1 (995) 38.3 (811) 37.9 (960) 38.5 (2584)
Separated/Divorced/Widowed 1.4 (35) 2.1 (45) 2.1 (52) 1.9 (125)
Don’t know/Missing 17.4 (431) 19.1 (405) 18.2 (462) 18.6 (1245)
Education, % (n)
No formal education 23.9 (594) 26.0 (552) 25.3 (640) 24.8 (1665)
Primary (grade 1 to 7) 6.3 (156) 6.5 (138) 6.8 (172) 6.4 (432)
Secondary+ (≥ grade 8) 69.8 (1731) 67.5 (1430) 68.0 (1722) 68.7 (4606)
Area of residency, % (n)
Rural 59.9 (1485) 52.7 (1117) 60.5 (1532) 58.3 (3905)
Peri-urban 32.8 (813) 47.3 (1003) 26.5 (671) 33.9 (2275)
Urban 7.4 (183) 0.0 (0) 13.1 (331) 7.8 (523)
EPIC, Empowering People through Informed Choices for HIV; IQR, interquartile range
a
95% confidence intervals were calculated using the cumulative probabilities of the binomial distribution.
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chance of winning a lottery for a larger amount did not result
in any significant difference [19]. Similarly, when either fixed
incentives or a lottery were provided among adolescents in
Zimbabwe, fixed incentives better increased HIV testing
uptake than a lottery [20]. We then offered home-based HIV
testing which provided the convenient option once someone is
nudged to accept testing.
We have not observed any effect of the male-sensitive HIV-
specific decision support application (EPIC-HIV 1) on the
uptake of home-based HIV testing. The application was devel-
oped to address the most important perceived barriers for
the uptake of HCT such as psychosocial factors, or existing
norms and encourage to take immediate action towards HCT
[38,39]. However, unlike financial incentives which bring imme-
diate and tangible benefit, overcoming psychosocial barriers
through improving intrinsic motivation can be an iterative and
slow process. Since HCT was offered right after the partici-
pants had listened to EPIC-HIV, they might have not yet been
ready to make immediate action towards HCT. Nevertheless,
in the post-intervention satisfaction surveys, 96% of partici-
pants who received EPIC-HIV 1 found EPIC-HIV 1 acceptable
and motivated them to test, and almost everyone reported







Risk ratios (95% CI)
N = 13,838 N = 1759 N = 2865
No. (%) No. (%)
Intervention group analysis
Financial incentives only 2481 686 (27.7) 680 (27.4) 1.55 (1.31 to 1.82)
Financial incentives plus EPIC-HIV 2120 605 (28.5) 566 (26.7) 1.51 (1.21 to 1.87)
EPIC-HIV only 2534 468 (18.5) 430 (17.0) 0.96 (0.76 to 1.20)
Standard of care 6703 n/a 1189 (17.7) Reference
Factorial analysis
Financial incentives 4601 1252 (27.2) 1246 (27.1) 1.55 (1.34 to 1.79)
No financial incentives 9237 n/a 1619 (17.5) Reference
Factorial analysis
EPIC-HIV 4654 1037 (22.3) 996 (21.4) 1.05 (0.85 to 1.30)
No EPIC-HIV 9184 n/a 1869 (20.4) Reference
EPIC, Empowering People through Informed Choices for HIV.
Figure 2. Risk ratio (RR) of HIV testing uptake in the full intent-to-treat analysis among all eligible men. The circle symbol with the error bar
represents the RR with 95% confidence interval in each arm compared to the standard of care arm. The percentage (%) indicates the per-
centage of HIV testing uptake.
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being empowered with the information from the app [40,41],
suggesting that engagement with EPIC-HIV 1 would poten-
tially lead to better uptake of home-based HIV testing or link-
age to care in the future.
The overall population coverage of HIV testing during this
single round of testing was relatively low at 21% (with 32% of
men away from home at the time of the fieldworker visits and
33% choosing not to participate in the annual population-
based HIV testing), although over several rounds of testing,
both the cumulative contact rate and the level of HIV testing
would increase. For example the consent rate to at least one
HIV test reached over 75% between 2005 and 2016 [31],
and approximately half of the eligible individuals consented at
least twice within five years of becoming eligible [42]. Never-
theless, consistently reaching men for HIV testing and treat-
ment remains a persistent challenge in this population and
across multiple contexts [14,22,43]. A recent systematic
review showed that acceptability of home-based HIV testing
greatly varies from 58.1% to 99.8% but with the high pooled
proportion of 83.3% throughout sub-Saharan Africa [44]. In
the area neighbouring communities, where the ANRS TasP
12249 Trial was conducted, the uptake of home-based HIV
testing was also high at 82.9% [12]. When we limited our anal-
ysis to those who were present at home and offered the test-
ing, the overall uptake of HIV testing was around 65%, and
significantly higher in the intervention arms than in the SoC
arm. Thus, it might require more than one visit to offer HIV
testing and intervention in order to have a substantial impact
at a population level.
Another challenge for delivering home-based HIV testing is
frequent short-term mobility and long-term migration. In the
study area, more than 20% of the residents migrate at least
once in a given year, putting them at a higher risk of HIV acqui-
sition and lack of access to HIV testing, prevention, or treat-
ment services [45]. Other innovative approaches have been
shown effective to increase the uptake of HCT such as provi-
sion of HIV self-testing kits during delivery of home-based HIV
testing services [46], at the community [47], or through female
partners attending antenatal care clinics [19] as well as finding
men and offering tests at convenient locations (e.g. workplace)
or via mobile testing [48,49]. Financial incentives coupled with
innovative approaches to reach men and offer HIV testing at
different settings or improve access to self-testing kits may fur-
ther improve the uptake of HIV testing.
The trial will further quantify the effect of financial micro-
incentives and EPIC-HIV applications on enhancing linkage to
care within three months to constitute the second primary
outcome of the trial in late 2020. We will also quantify the
long-term effects on HIV-related mortality among men and
HIV incidence among young women by 2022 [34]. The trial
has also collected detailed information on resources used to
implement and deliver the interventions using micro-costing
and a time-and-motion approach and will quantify the cost-
effectiveness of financial micro-incentives and EPIC-HIV appli-
cation to improve HIV testing uptake and linkage to care. A
study in Tanzania showed that willingness-to-accept estimates
for financially incentivized universal HIV testing among adults
were $1.3-$6.4 and considered highly cost-effective [50], but
there is very limited evidence for cost-effectiveness of both
financial incentives and behavioural intervention in the general
population using the data from randomized clinical trials. Our
study findings will provide important insights into the efficacy,
cost-effectiveness and sustainability of once-off micro-incen-
tives and decision support application to reach men and
improve long-term population health outcomes in hyperen-
demic HIV settings.
The study has several important strengths. The study was
the first of its kind and was delivered as a community-ran-
domized clinical trial among over 13,800 men in 45 communi-
ties nested within one of the world’s largest ongoing
population-based HIV cohorts. This allowed the unbiased mea-
suring the effect of the interventions where home-based HIV
testing at households was a standard of care, controlling for
potential contextual factors and differences across the com-
munities, and provided sufficient power to detect the effects
of interventions. In some randomized clinical trials, treatment
non-adherence or crossover among randomized groups may
cause treatment contamination, thus a statistical approach like
instrumental variables would be beneficial to adjust for treat-
ment contamination [51]. In our study, however, every partici-
pant was offered and received interventions as randomized
(i.e. no contamination of randomized interventions), further
validating our intention-to-treat analysis. However, the study
is not without limitations. In particular, men who did not par-
ticipate in the annual HIV testing survey were not eligible to
receive interventions in the study, thus ultimately limiting the
potential population coverage of the interventions.
5 | CONCLUSIONS
In summary, we found that a small, once-off, financial incentive
significantly improved the uptake of home-based HIV testing
by more than 50% among men in this large community-ran-
domized clinical trial. In contrast, the counselling and testing
application which was designed to serve as an intrinsic motiva-
tor for HIV testing did not increase the uptake of home-based
testing. Financial micro-incentives could be considered as an
effective strategy to encourage the uptake of home-based
HIV testing, especially among the unreached population with a
lower uptake of HCT.
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